Drug · CHEMBL90555

VINCRISTINE

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. VINCRISTINE. Drugs and targets, record CHEMBL90555. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL90555

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: VINCRISTINE; ChEMBL
ChEMBL ID: CHEMBL90555; ChEMBL
Type: Small molecule; ChEMBL
Other names: 22-oxovincaleukoblastine, Leucristine, Leurocristine, Oncotcs, Tecnocris, Vincaleukoblastine, 22-oxo-, Vincristin, Vincristina, Vinkristin; ChEMBL
Other form: VINCRISTINE SULFATE, CHEMBL501867; Drugs and targets
InChIKey: OGWKCGZFUXNPDA-XQKSVPLYSA-N; ChEMBL
Open Targets' highest stage: Approval, for 1 of its 134 diseases, from ATC; Open Targets

Targets15

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
TUBA1A	Tubulin	Tubulin inhibitor	INHIBITOR	https://conductscience.org/library/genes/7846
TUBA1B	Tubulin	Tubulin inhibitor	INHIBITOR	https://conductscience.org/library/genes/10376
TUBA1C	Tubulin	Tubulin inhibitor	INHIBITOR	https://conductscience.org/library/genes/84790
TUBA3C	Tubulin	Tubulin inhibitor	INHIBITOR	https://conductscience.org/library/genes/7278
TUBA3E	Tubulin	Tubulin inhibitor	INHIBITOR	https://conductscience.org/library/genes/112714
TUBA4A	Tubulin	Tubulin inhibitor	INHIBITOR	https://conductscience.org/library/genes/7277
TUBB	Tubulin	Tubulin inhibitor	INHIBITOR	https://conductscience.org/library/genes/203068
TUBB1	Tubulin	Tubulin inhibitor	INHIBITOR	https://conductscience.org/library/genes/81027
TUBB2A	Tubulin	Tubulin inhibitor	INHIBITOR	https://conductscience.org/library/genes/7280
TUBB2B	Tubulin	Tubulin inhibitor	INHIBITOR	https://conductscience.org/library/genes/347733

1 to 10 of 15Source ChEMBL

See all 15 targets

Diseases134

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
diffuse large B-cell lymphoma	Phase 3	ClinicalTrials.gov	160	160	https://conductscience.org/library/drugs?q=MONDO_0018905
acute lymphoblastic leukemia	Phase 3	ClinicalTrials.gov	131	131	https://conductscience.org/library/drugs?q=MONDO_0004967
non-Hodgkin lymphoma	Phase 3	ClinicalTrials.gov	65	65	https://conductscience.org/library/drugs?q=MONDO_0018908
follicular lymphoma	Phase 3	ClinicalTrials.gov	37	37	https://conductscience.org/library/drugs?q=MONDO_0018906
Hodgkins lymphoma	Phase 3	ClinicalTrials.gov	34	34	https://conductscience.org/library/drugs?q=MONDO_0004952
mature T-cell and NK-cell non-Hodgkin lymphoma	Phase 3	ClinicalTrials.gov	28	28	https://conductscience.org/library/drugs?q=MONDO_0000430
mantle cell lymphoma	Phase 3	ClinicalTrials.gov	27	27	https://conductscience.org/library/drugs?q=MONDO_0018876
neuroblastoma	Phase 3	ClinicalTrials.gov	25	25	https://conductscience.org/library/drugs?q=MONDO_0005072
Ewing sarcoma	Phase 3	ClinicalTrials.gov	24	24	https://conductscience.org/library/drugs?q=MONDO_0012817
lymphoblastic lymphoma	Phase 3	ClinicalTrials.gov	22	22	https://conductscience.org/library/drugs?q=MONDO_0000873

1 to 10 of 134Source Open Targets

See all 134 diseases

Trials809

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more rests on that reading alone and is shown because the trial's posted result groups or NLM's indexing of its papers name the drug. 8 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT00103285	Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	Phase 3	5,377	2018-07-11	vincristine	Its name	ClinicalTrials.gov
NCT00075725	Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia	Phase 3	3,154	2015-08-06	vincristine	Its name	ClinicalTrials.gov
NCT01287741	A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)	Phase 3	1,418	2017-08-17	vincristine	Its name	ClinicalTrials.gov
NCT01332968	A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)	Phase 3	1,401	2017-06-07	vincristine	Its name	ClinicalTrials.gov
NCT00003389	Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma	Phase 3	854	2015-09-03	vincristine	Its name	ClinicalTrials.gov
NCT01855750	A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma	Phase 3	838	2019-03-19	vincristine	Its name	ClinicalTrials.gov
NCT00352534	Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor	Phase 3	808	2017-05-15	vincristine	Its name	ClinicalTrials.gov
NCT00486759	A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma	Phase 3	787	2012-12-31	vincristine	Its name	ClinicalTrials.gov
NCT00278408	Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma	Phase 3	700	2025-08-26	vincristine	Its name	ClinicalTrials.gov
NCT00083551	UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy	Phase 3	668	2015-09-22	vincristine	Its name	ClinicalTrials.gov

1 to 10 of 809

See all 809 trials

Comparisons in its trials127

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
All Patients for Induction, MRD Negative vs All Patients for Induction, MRD Positive: Early Marrow Status (EMS) by MRD Status End Induction (Day 29)	4,378 of 4,609	258 of 362	4,971	NCT00103285	Trial comparisons
Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy: serious adverse events	269 of 701	312 of 702	1,403	NCT01287741	Trial comparisons
Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy: deaths from any cause	111 of 692	104 of 698	1,390	NCT01332968	Trial comparisons
Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy: serious adverse events	309 of 692	361 of 698	1,390	NCT01332968	Trial comparisons
Arm A (ABVD) vs Arm B (Stanford V): serious adverse events	355 of 414	401 of 422	836	NCT00003389	Trial comparisons
Treatment Arm B: Ibrutinib+R-CHOP vs Treatment Arm A: Placebo+R-CHOP: deaths from any cause	78 of 416	78 of 418	834	NCT01855750	Trial comparisons
Treatment Arm B: Ibrutinib+R-CHOP vs Treatment Arm A: Placebo+R-CHOP: serious adverse events	221 of 416	143 of 418	834	NCT01855750	Trial comparisons
Arm A (ABVD) vs Arm B (Stanford V): Incidence of Second Cancers	15 of 395	19 of 399	794	NCT00003389	Trial comparisons
Bevacizumab + Rituximab + CHOP vs Placebo + Rituximab + CHOP: serious adverse events	224 of 395	173 of 386	781	NCT00486759	Trial comparisons
Thalidomide vs No Thalidomide: serious adverse events	323 of 323	345 of 345	668	NCT00083551	Trial comparisons

1 to 10 of 127

See all 127 comparisons in its trials

Papers from its trials689

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41249450	RESULT	1	PubMed
41035796	RESULT	1	PubMed
40751881	RESULT	1	PubMed
40167581	RESULT	1	PubMed
39415930	RESULT	1	PubMed
38501390	RESULT	1	PubMed
38501389	RESULT	1	PubMed
38231288	RESULT	1	PubMed
37731389	RESULT	1	PubMed
37216396	RESULT	1	PubMed

1 to 10 of 689

See all 689 papers from its trials

Tests in its trials12

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

Test	Trials naming it as an outcome	Source
Verbal Learning	3	ConductCognition
Symbol Scan Task	2	ConductCognition
Trail Making Test A	2	ConductCognition
Verbal Fluency	2	ConductCognition
Arithmetic Fluency Task	1	ConductCognition
Block Copy Test	1	ConductCognition
Continuous Performance Test	1	ConductCognition
Digit Span Test	1	ConductCognition
Hidden Path Learning	1	ConductCognition
1-Back Task	1	ConductCognition

1 to 10 of 12

See all 12 tests in its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL90555

GET https://conductscience.org/api/drugs/v1/CHEMBL90555/diseases?page=2

API reference For AI assistants